In the Letter entitled "Relapse of Depressive Symptoms After Discontinuing
Sertraline," published in the July 28, 1999, issue of THE JOURNAL (1999;282:323-324),
the financial disclosure statement for the reply letter is incomplete. The
following should be added to what was published: "Drs Gelenberg, Rush, Koran,
Klein, McCullough, Kocsis, Kornstein, Schatzberg, and Fawcett have served
as consultants to and/or received grant support from numerous pharmaceutical
companies, some of which manufacture sertraline or other selective serotonin
reuptake inhibitors. In addition, Drs Gelenberg, Kocsis, and Schatzberg own
stock in 1 or more companies that manufacture sertraline or other selective
serotonin reuptake inhibitors, and Dr LaVange is affiliated with Quintiles
Inc, a for-profit contract research organization, and in that role provides
statistical consulting for many pharmaceutical companies, including Pfizer
Inc."